Producer
AptarGroup, Inc.
Global leader in dispensing systems — pumps, sprayers, airless and aerosol valves — for beauty, personal care and pharma. >15% of the cosmetic packaging market; dominant in the functional dispenser.
3
Inputs supplied
3
Goods downstream
1
Facilities
0
Stories
What they make
3 inputs AptarGroup, Inc. supplies
Click an input to see every good that depends on it, every country that produces it, and every other company in the supply chain.
Where it shows up
Goods downstream
Essential goods that depend on something AptarGroup, Inc. makes — pick one to see the full supply chain.
What else they do
Business segments
The company's full revenue map — where this supply-chain role fits within their broader business.
Pharma (drug delivery)
Beauty
Closures (food/beverage/home)
Intelligence
What's known
Sourced claims about this company's role in supply chains — chokepoints, concentration, incidents, dual-use connections.
Did you know2016
The company behind perfume sprayers and lotion pumps is also in the critical path of emergency medicine. AptarGroup, which built its business on consumer spray valves and pumps, makes the nasal-spray device that delivers Narcan (naloxone) — the first FDA-approved ready-to-use nasal opioid-overdose reversal (developed with Adapt Pharma, 2016) — and is a leading supplier of the metered valves inside pressurized asthma/COPD inhalers (pMDIs). The same precision spray engineering that mists cologne doses life-saving drugs to the milligram, so a beauty-packaging name quietly underpins overdose rescue and respiratory care. [verify: Narcan unit-dose device + DF30 pMDI valve leadership both independently confirmed]
Fierce Pharma ↗Chokepoint
A drug-delivery dispenser looks trivial but is a high-switching-cost chokepoint. On a regulated inhaled or nasal product, the device — the valve or pump — is part of the FDA-approved combination product, so swapping the dispenser requires re-validation and new regulatory filings. That locks pharma brands to their device supplier far more tightly than a commodity package would. Aptar's dominance in OINDP (orally-inhaled and nasal drug products) systems means an unglamorous component carries outsized regulatory lock-in and supply-chain leverage — a single-supplier dependency hiding inside approved medicines. [verify: Aptar OINDP leader + device-constituent revalidation real; not literally sole-supplier]
Quantics Biostatistics ↗